Projects per year
Abstract
Natural killer (NK) cell activity is essential for initiating (TCGA), we show that patients with metastatic cutaneous antitumor responses and may be linked to immunotherapy melanoma have an improved survival rate if their tumor success. NK cells and other innate immune components shows evidence of NK cell infiltration. Furthermore, these could be exploitable for cancer treatment, which drives the survival effects are enhanced in tumors that show higher need for tools and methods that identify therapeutic ave-expression of genes that encode NK cell stimuli such as the nues. Here, we extend our gene-set scoring method singscore cytokine IL15. Using this signature, we then examine tran-to investigate NK cell infiltration by applying RNA-seq scriptomic data to identify tumor and stromal components analysis to samples from bulk tumors. Computational that may influence the penetrance of NK cells into solid methods have been developed for the deconvolution of tumors. Our results provide evidence that NK cells play a immune cell types within solid tumors. We have taken the role in the regulation of human tumors and highlight NK cell gene signatures from several such tools, then curated potential survival effects associated with increased NK cell the gene list using a comparative analysis of tumors and activity. Our computational analysis identifies putative gene immune cell types. Using a gene-set scoring method to targets that may be of therapeutic value for boosting NK cell investigate RNA-seq data from The Cancer Genome Atlas antitumor immunity.
Original language | English |
---|---|
Pages (from-to) | 1162-1174 |
Number of pages | 13 |
Journal | Cancer Immunology Research |
Volume | 7 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2019 |
Projects
- 3 Finished
-
Identification of CIS as a potent checkpoint in NK cell-mediated tumour immunity
Huntington, N. (Primary Chief Investigator (PCI)), Smyth, M. J. (Chief Investigator (CI)), Vivier, É. (Chief Investigator (CI)) & Nicholson, S. E. (Chief Investigator (CI))
National Health and Medical Research Council (NHMRC) (Australia)
1/06/19 → 31/12/20
Project: Research
-
Identification and targeting of a potent NK cell “checkpoint” in tumour immunity
Huntington, N. (Primary Chief Investigator (PCI))
National Health and Medical Research Council (NHMRC) (Australia)
1/02/19 → 31/12/20
Project: Research
-
Identification of E-protein complexes controlling natural killer cell fate and tumour immunity
Huntington, N. (Primary Chief Investigator (PCI)), Corcoran, L. M. (Chief Investigator (CI)), Vivier, É. (Chief Investigator (CI)) & Nicholson, S. E. (Chief Investigator (CI))
National Health and Medical Research Council (NHMRC) (Australia)
1/02/19 → 31/12/19
Project: Research